Related Experiment Video
Updated: May 8, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves
Published on: October 17, 2013
New CoreValve Evolut 23 mm technology for treatment of degenerated bioprosthesis
Dennis Zavalloni1, Mauro De Benedictis2, Paolo Pagnotta1
1U.O. Emodinamica e Cardiologia Invasiva, Istituto Clinico Humanitas, IRCCS, Rozzano, Milano, Italy.
Abstract:
The treatment of degenerated surgical bio-prosthetic heart valves (BHV) has been reported as a novel indication for TAVI. The intervention may be complicated by high residual transvalvular gradients and coronary ostia obstruction, especially in small size BHV. We report two cases of BHVs treated with the new CoreValve Evolut 23 mm highlighting the importance of fluoroscopic guidance, based on BHV markers, in achieving a correct TAVI implantation. The small dimensions of the new CoreValve Evolut 23 allowed us to obtain low residual gradients even in this particular subset of degenerated BHV.
Related Concept Videos
Mitral Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Aortic Regurgitation III: Medical Management
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse III: Nursing Management
Mitral Valve Prolapse I: Introduction
